Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free SPRY Stock Alerts

ARS Pharmaceuticals (SPRY) Earnings Date, Estimates & Call Transcripts

ARS Pharmaceuticals logo
$9.39 +0.36 (+3.96%)
As of 10:22 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ARS Pharmaceuticals Earnings Summary

ARS Pharmaceuticals posted Q4 2025 earnings on March 9, 2026, reporting an EPS of -$0.42, which hit analysts' consensus estimates of -$0.42. Quarterly revenue was reported to be $28.09 million, above the consensus estimate of $25.58 million. With a trailing EPS of -$1.75, ARS Pharmaceuticals' earnings are expected to grow next year, from ($1.54) to ($0.54) per share.

Upcoming
Earnings Date
May. 13Before Market OpensEstimated
Consensus EPS
(Mar. 9)
-$0.42
Actual EPS
(Mar. 9)
-$0.42
Actual Revenue
(Mar. 9)
$28.09M

Q4 2025 Earnings Resources

SPRY Upcoming Earnings

ARS Pharmaceuticals' Q1 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2026 Earnings Report
Powered by Quartr
Get ARS Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

SPRY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SPRY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ARS Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20263-$0.49-$0.47-$0.48
Q2 20263-$0.38-$0.30-$0.35
Q3 20263-$0.28-$0.08-$0.18
Q4 20263-$0.37-$0.22-$0.29
FY 2026 12 -$1.52 -$1.07 -$1.29
Q1 20271-$0.32-$0.32-$0.32
Q2 20271-$0.04-$0.04-$0.04
Q3 20271$0.32$0.32$0.32

ARS Pharmaceuticals Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/13/2026
(Estimated)		-------
3/9/2026Q4 2025-$0.42-$0.42--$0.42$25.58M$28.09M
11/10/2025Q3 2025-$0.45-$0.52 -$0.07-$0.52$28.87M$32.50M
8/13/2025Q2 2025-$0.41-$0.46 -$0.05-$0.46$12.92M$15.72M
5/14/2025Q1 2025-$0.35-$0.35--$0.35$7.48M$7.97M
3/20/2025Q4 2024-$0.04$0.52+$0.56$0.52$15.46M$86.58M
8/6/2024Q2 2024-$0.12-$0.13 -$0.01-$0.13$2.00M$0.50M
5/9/2024--$0.11-$0.11--$0.11--

Data powered by Fiscal.ai.

ARS Pharmaceuticals Earnings - Frequently Asked Questions

ARS Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 13th, 2026 based off last year's report dates. Learn more on SPRY's earnings history.

In the previous quarter, ARS Pharmaceuticals (NASDAQ:SPRY) reported ($0.42) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.42). Learn more on analysts' earnings estimate vs. SPRY's actual earnings.

The conference call for ARS Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for ARS Pharmaceuticals' latest earnings report can be read online.
Read Transcript

ARS Pharmaceuticals (NASDAQ:SPRY) has a recorded annual revenue of $84.28 million.

ARS Pharmaceuticals (NASDAQ:SPRY) has a recorded net income of -$171.30 million. SPRY has generated -$1.75 earnings per share over the last four quarters.

ARS Pharmaceuticals' earnings are expected to grow from ($1.54) per share to ($0.54) per share in the next year.

Related Companies
Earnings Tools

This page (NASDAQ:SPRY) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
A U.S. Resource Gap Is a National Issue - and Opportunity
America still does not domestically produce one mineral tied to batteries, energy storage, and national defens...
i2i Marketing Group, LLC | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
The media's calling it "the biggest IPO in Wall Street history." But I'm not buying it. Institutions got into ...
Decentralized Masters | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Trump and Elon are BACK
15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...
InvestorPlace | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel